NCT00398320View on ClinicalTrials.gov

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Capecitabine

850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle

DRUG

Oxaliplatin

130 mg/m2 intravenously on day 1 of a 21 day cycle

DRUG

Bevacizumab

7.5mg/kg Intravenous on day 1 of a 21 day cycle

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Pamela L. Kunz

OTHER

NCT00398320 - Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter